Coming Soon

Data on adverse effects of pharmaceuticals Set

The PRS ADR report ⁇ signal mining data sets ⁇ adverse event causality assessment ⁇ drug alert AI

ADRreports
Signal dimension
Time Span
SRS/RWD
Source
Coming Soon
Status

Dataset Overview

Data on adverse effects of pharmaceuticals Setis provided byChangsha Langhui Information Technology Co., Ltd.The core dimensions of the drug-incident combination (PRR/ROR/IC/EBGM) are supported by strict de-sensitization, by the compilation of data from the self-reported system (SRS) on the adverse drug response and structured signal mining, covering the description of the adverse event, the severity rating (CTRAE), the causality assessment (Naranjo/WHO-UMC), the drug-incident combination (PRR/ROR/IC/EBGM) and subsequent evaluation.

Dataset NameData on adverse effects of pharmaceuticals Set
Data TypeSDS ADR report + signal mining structured data + structured JSON
Core ContentDefective incident description (MedDRA code), severity classification (CTCAE), causality assessment (Naranjo/WHO-UMC), suspected drugs/mergers, drug-incident combination signals, PRR/ROR/IC/EBGM signal detection indicators
Source DataNational Drug Negative Response Monitoring System (RSS), voluntary report of the ADR of the medical institution, and documentary case safety report (ICSR)
Use CasesDrug alert AI, security signal mining, adverse event causality assessment, post-market evaluation of drugs, development of risk management plan (RMP)
Format OutputStructured JSON + CSV Export + API Access
StatusComing Soon

Core Data Dimensions

The data set is organized in accordance with the ICH drug alert guide (E2B/E2C/E2D) and covers the full life cycle of ADR reporting and signal management links.

Dimension CategoryField CountTypical FieldsValue Tier
Report identifier8Report number (sole global case marking), type of report (sponsible/documentation/research), source of report, date of report, reporting country/area, reporting person ' s qualifications (doctor/pharmacist/patient), severity mark, emergency report markBasic Identifier
Patient Information8Age of patients (dissensitization group), gender, weight (dissensitization zone), history of adverse reaction of past drugs, relevant medical history (MedDRA code), combination of diseases, pregnancy/lactation mark, fate (rehabilitation/improved/unresilient/infective/death)上下文信息
Bad event14Defective (MedDRA LLT/PT code), classification of organs in the MedDRA SOC system, date of occurrence, end date, duration, severity classification (CTRAE v. 5.0 1 - 5), criteria for determination of serious adverse events (SAE) (death/threatening/hospital extension/disability/incapacitation), ending of incidentCore Dimensions
Suspected drugs12Suspected generic/trade name, approval number, ATC code, formulation, route of delivery, quantity of use, date of commencement of use, drug adaptation certificate, stop-to-use response, re-inducing response, drug batch number (dissensitization), drug producerCore Dimensions
Combined medicine8Combined drug use name, date of commencement of drug use, certificate of adaptation, route of delivery, relevance to bad event time, combination drug-incident interaction mark, DDI risk assessment, CYP450 enzyme-related interactionAdvanced Analysis
Causation assessment10Naranjo Quantum Rating ( ⁇ 9: positive; 5-8: likely; 1-4: possible; ⁇ 0: suspicious); WHO-UMC Causation Rating (positive/possible/possible/not possible/not possible/not possible), to stimulate reactions, re-inducing reactions, time reasonableness, laboratory examination support, exclusion of other causesAdvanced Analysis
Signal detection12Medicines - Event combination (DEC), PRR values and 95% CI, ROR values and 95% CI, IC values and 95% CI (Bayes), EBGM values and 90% CI (Empirical Bayes), signal threshold determination (PRR ⁇ 2 and ⁇ 4 and N ⁇ 3), signal intensity classification, signal verification statusSignal mining
Metadata6Date of data entry, source system, data quality rating, completeness rating, dissensitisation, version numberQuality Management

AI Application Scenarios

Drug alert signal intelligence dig.

Based on the ADR report coded with MedDRA, automatic detection, prioritization and signal validation of drug event signals are achieved using signal detection algorithms such as PRR/ROR/IC/EBGM.

ACVA AI

Naranjo/WHO-UMC training NLP model for the assessment dimension of causation, resulting in automatic causality assessment and structured entry in an example safety report (ICSR).

Post-market security re-evaluation

The real world ADR data-aided medicines are re-evaluated for safety, identifying rare/late-incident adverse events, assessing benefit-risk balance, and supporting the development of risk management plans (RMPs).

Medicinal Alert 'Aide.

The ADR reports automatic classification, stratification and projection of gravity, and the auxiliary drug alert team conducts efficient case-by-case and aggregated analysis.

Common problems

When will the dataset go live?
The DRMS data set is currently in the data integration and desensitization phase and is expected to be formally launched in the near future. The data set is a collection of multi-source ADR data from the National Drug Adverse Response Monitoring System (SRS) and spontaneous reports from medical institutions and is being validated through the MedDRA code standardization and signal detection algorithm.
Does the ADR report contain a MedDRA code?
Yes. All adverse incident descriptions will be coded with the PT in the MedDRA standard term and map to SOC (systemic organ classification), as required by the ICH Guide, ensuring consistency with international drug alert data standards and supporting integrated signal analysis across data sets and regions.

Need a customized data solution?

Changsha Langhui Information Technology Co., Ltd. The DataAssetsAPI platform is dedicated to providing high-quality, compliant data assets to AI enterprises and scientific institutions.

Data sample preview · Customized data solution · ProSupport